Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-05-09 | Forward | 507:500 |
Rafael Holdings, Inc. invests in early-stage pharma and real estate assets in the US and Israel, developing therapies like CPI-613 for cancer and managing commercial properties.

A drug candidate in pivotal Phase 3 clinical trials for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disorder. It represents the company's lead therapeutic and primary focus for future commercialization.
| Icon | PRODUCT | Q1-2023 | Q2-2023 | Q3-2023 | Q4-2023 |
|---|---|---|---|---|---|
![]() | Real Estate | — | $70K | — | $209K ▲ |
![]() | Parking | $66K | — | $66K | — |
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
FTHM | $0.68 | COMPARE |
OPAD | $4.36 | COMPARE |
AHT | $3.25 | COMPARE |
AIRE | $1.61 | COMPARE |
OMH | $0.07 | COMPARE |